![An van Es-Johansson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
An van Es-Johansson
Director/Board Member at
SAVARA INC.
Net worth: 389 029 $ as of 29/06/2026
Profile
An van Es-Johansson currently works at Plus Therapeutics, Inc., as Independent Non-Executive Director from 2020, Lumos Pharma Sub, Inc., as Director from 2021, Savara, Inc., as Independent Director from 2019, van Es Consulting AB, as Director, and Agendia, Inc., as Member-Supervisory Board.
Dr. van Es-Johansson also formerly worked at BioInvent International AB, as Independent Director from 2016 to 2021, Medivir AB, as Independent Director from 2019 to 2022, IRLAB Therapeutics AB, as Independent Director from 2022 to 2023, Lumos Pharma, Inc., as Independent Director from 2021 to 2024, Swedish Orphan Biovitrum AB, as VP & Head-EMENAR Medical Affairs from 2013 to 2018, AlzeCure Pharma AB, as Chief Medical Officer & Head-Development from 2020 to 2021, and Agendia NV, as Member-Supervisory Board from 2019 to 2024.
Dr. van Es-Johansson received his doctorate degree from Erasmus University Rotterdam.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SAVARA, INC. 0.03% | 05/04/2026 | 62,500 ( 0.03% ) | 385 000 $ | 29/06/2026 |
| 30/06/2026 | 922 ( 0.01% ) | 4 029 $ | 29/06/2026 |
An van Es-Johansson active positions
| Companies | Position | Start |
|---|---|---|
| SAVARA INC. | Director/Board Member | 02/12/2019 |
| PLUS THERAPEUTICS, INC. | Director/Board Member | 31/12/2019 |
van Es Consulting AB | Director/Board Member | - |
Agendia, Inc.
 Agendia, Inc. Pharmaceuticals: MajorHealth Technology Provides genomics technologies for clinical management of cancer | Director/Board Member | - |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Director/Board Member | 31/01/2021 |
Former positions of An van Es-Johansson
| Companies | Position | End |
|---|---|---|
| LUMOS PHARMA, INC. | Director/Board Member | 11/12/2024 |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Operates gene expression analysis-based diagnostics company which development and commercialization of diagnostic tests using tumor gene expression profiling | Director/Board Member | 31/05/2024 |
| IRLAB THERAPEUTICS AB | Director/Board Member | 31/01/2023 |
| MEDIVIR AB | Director/Board Member | 04/05/2022 |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of An van Es-Johansson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
60
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
BioInvent International AB
 BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
Medivir AB
 Medivir AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Operates gene expression analysis-based diagnostics company which development and commercialization of diagnostic tests using tumor gene expression profiling | Health Services |
Plus Therapeutics, Inc.
 Plus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops radio therapeutics products | Health Technology |
Erasmus University Rotterdam
 Erasmus University Rotterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Provides genomics technologies for clinical management of cancer | Health Technology |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Health Services |
IRLAB Therapeutics AB
 IRLAB Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for neurological diseases | Health Technology |
Savara, Inc.
 Savara, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals to treat respiratory diseases | Health Technology |
AlzeCure Pharma AB
 AlzeCure Pharma AB BiotechnologyHealth Technology Engages in research, development, manufacture and sale of pharmaceutical products for neuro diseases | Health Technology |
van Es Consulting AB | |
Lumos Pharma, Inc.
 Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases | Health Technology |
- Stock Market
- Insiders
- An van Es-Johansson
Choose MarketScreener 
